Equities research analysts forecast that Syros Pharmaceuticals Inc (NASDAQ:SYRS) will post $420,000.00 in sales for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Syros Pharmaceuticals’ earnings, with estimates ranging from $400,000.00 to $450,000.00. Syros Pharmaceuticals reported sales of $380,000.00 during the same quarter last year, which indicates a positive year-over-year growth rate of 10.5%. The firm is expected to report its next quarterly earnings report on Tuesday, August 6th.
According to Zacks, analysts expect that Syros Pharmaceuticals will report full-year sales of $1.72 million for the current financial year, with estimates ranging from $1.65 million to $1.80 million. For the next financial year, analysts expect that the company will report sales of $1.87 million, with estimates ranging from $1.60 million to $2.00 million. Zacks’ sales calculations are a mean average based on a survey of research firms that follow Syros Pharmaceuticals.
Syros Pharmaceuticals (NASDAQ:SYRS) last announced its earnings results on Wednesday, May 1st. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.08. The firm had revenue of $0.45 million for the quarter, compared to analyst estimates of $0.42 million. Syros Pharmaceuticals had a negative return on equity of 74.28% and a negative net margin of 3,012.04%.
In related news, Director Srinivas Akkaraju bought 533,332 shares of the business’s stock in a transaction on Tuesday, April 9th. The stock was acquired at an average cost of $7.50 per share, with a total value of $3,999,990.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 14.80% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Arbitrage SA acquired a new stake in shares of Syros Pharmaceuticals in the 1st quarter worth $48,000. Bank of America Corp DE increased its stake in shares of Syros Pharmaceuticals by 205.9% in the 4th quarter. Bank of America Corp DE now owns 17,400 shares of the company’s stock worth $98,000 after acquiring an additional 11,711 shares during the last quarter. Rhumbline Advisers increased its stake in shares of Syros Pharmaceuticals by 51.4% in the 4th quarter. Rhumbline Advisers now owns 32,406 shares of the company’s stock worth $181,000 after acquiring an additional 10,995 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. increased its stake in shares of Syros Pharmaceuticals by 8.3% in the 1st quarter. Los Angeles Capital Management & Equity Research Inc. now owns 40,380 shares of the company’s stock worth $369,000 after acquiring an additional 3,100 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Syros Pharmaceuticals by 10.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 77,654 shares of the company’s stock worth $925,000 after acquiring an additional 7,062 shares during the last quarter. 56.16% of the stock is owned by institutional investors and hedge funds.
Shares of SYRS stock opened at $7.52 on Wednesday. The company has a fifty day moving average price of $6.46. The company has a quick ratio of 5.19, a current ratio of 5.19 and a debt-to-equity ratio of 0.02. The stock has a market cap of $283.43 million, a price-to-earnings ratio of -3.94 and a beta of 1.27. Syros Pharmaceuticals has a fifty-two week low of $5.17 and a fifty-two week high of $13.18.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.
Further Reading: What is the Fibonacci sequence?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.